Island Pharmaceuticals Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Options exercise from existing substantial shareholder
- Completion of Galidesivir transaction
- Portfolio expansion achieved with acquisition of Galidesivir
- Successful Phase 2 clinical trial of ISLA-101
- Island completes $3.6 million placement
Later from Island Pharmaceuticals
- FDA meeting request lodged for Galidesivir
- FDA Meeting request granted
- US FDA Type C meeting briefing document submitted
- FDA confirms response timing for Galidesivir
- FDA agrees Animal Rule pathway and PRV eligibility
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals